Cassiopea Says Breezula Phase II Results Very Positive
I have covered Italian company Cassiopeia since 2014 (when it was called Cosmo Pharmaceuticals). The company is developing a topical anti-androgen hair loss product named Breezula (originally called CB-03-01). The chemical name for this product is Clascoterone.
Breezula will be available for both men and women. Several of my well known physician contacts in the hair loss world have told me great things about this product. Their feedback is based on what they saw at conferences or heard from colleagues.
Breezula Phase II Trials Very Successful
In July of last year, Cassiopeia stated that the interim Phase II clinical trial results for Breezula were very positive. Today, they released twelve month Phase II trial results with the same conclusion:
The presentation of the results is confusing, detailed, full of acronyms and somewhat open to interpretation. Note that “BID” in there stands for “twice per day” after conversion from Latin. Hopefully they release before and after photos at some point.
Breezula Target Area Hair Count Increase
Best case result highlighted in yellow:
Breezula Target Area Hair Width Increase
Best case result highlighted in yellow:
My gut feeling is that Breezula will be at least as effective as Finasteride and Minoxidil.
Clascoterone Summary
Some key points from the above linked article from Cassiopeia:
- If approved, Breezula (Clascoterone) will be the first FDA-approved topical anti-androgen for the treatment of androgenetic alopecia.
- Moreover, it would also be the first new drug approved for treating androgenetic alopecia since 1997. That year was when Propecia (aka Finasteride) was first approved to treat hair loss. That year was also when Tiger Woods last won the Master’s before this past weekend’s surprise.
- Based on these great results, Cassiopeia plans to proceed with 6-month Phase III trials in men in the fourth quarter of 2019, after consultation with the FDA. The company is also going to start proof-of-concept trials in women.
- Breezula works by blocking dihydrotestosterone (DHT) interaction with hair follicle androgen receptors.
- Clascoterone does not interfere with testosterone and other hormones in male subjects. Libido and sexual behavior changes have so far not been observed in clinical trials. Moreover, due to its rapid metabolism and localized activity, Clascoterone (Breezula) does not produce any systemic side effects.
In the past, I used to often state that perhaps an initial cure for hair loss would entail the usage of a cocktail of products. Each working via different mechanisms and chemical or biological reactions.
It is looking likely that Breezula will be one of the main products in this cocktail.
Note that Clascoterone cream to treat acne will be released by Cassiopeia before Breezula. The acne product is called Winlevi.
The post Cassiopea Says Breezula Phase II Results Very Positive appeared first on Hair Loss Cure 2020.